|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.780 USD | -4.40% |
|
+2.36% | -12.58% |
| 05-12 | Bolt Biotherapeutics reports first quarter 2026 financial results | RE |
| 05-12 | Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Company Valuation: Bolt Biotherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 182.7 | 48.96 | 42.52 | 20.48 | 10.5 | 9.185 | - | - |
| Change | - | -73.2% | -13.15% | -51.84% | -48.75% | -12.49% | - | - |
| Enterprise Value (EV) | -3.524 | -97.32 | -39.45 | 20.48 | 10.5 | 9.185 | 9.185 | 9.185 |
| Change | - | -2,661.37% | 59.46% | 151.92% | -48.75% | -12.49% | 0% | 0% |
| P/E ratio | -1.65x | -0.55x | -0.61x | -0.32x | -0.31x | -0.01x | -0.03x | -0.02x |
| PBR | 0.73x | 0.29x | 0.38x | - | - | - | - | - |
| PEG | - | 0x | 0x | 0.03x | 0x | -0x | 0x | -0x |
| Capitalization / Revenue | 145x | 8.55x | 5.4x | 2.66x | 1.36x | - | 3.94x | 2.3x |
| EV / Revenue | -0x | -0x | -0x | 0x | 0x | - | 3.94x | 2.3x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | 0x | 0x | 0x | -0x | -0x | -0.14x | -0.19x | -0.15x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -59.4 | -47.2 | -36.6 | -33 | -17.85 | -351.9 | -170 | -308.4 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1.26 | 5.729 | 7.876 | 7.69 | 7.695 | - | 2.333 | 4 |
| EBITDA | -83.1 | -79.08 | -65.12 | - | - | - | - | - |
| EBIT 1 | -92.79 | -90.32 | -76.2 | -73.05 | -36.11 | -65 | -47.5 | -60 |
| Net income 1 | -98.59 | -88.1 | -69.2 | -63.12 | -33.38 | -65 | -23.75 | -30 |
| Net Debt | -186.2 | -146.3 | -81.97 | - | - | - | - | - |
| Reference price 2 | 98.000 | 26.000 | 22.400 | 10.702 | 5.468 | 4.780 | 4.780 | 4.780 |
| Nbr of stocks (in thousands) | 1,864 | 1,883 | 1,898 | 1,914 | 1,919 | 1,922 | - | - |
| Announcement Date | 30/03/22 | 29/03/23 | 21/03/24 | 24/03/25 | 12/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.36x | - | - | - | 9.19M | |
| 29.67x | 7.58x | 22.75x | 0.06% | 50.1B | |
| 17.07x | 5.18x | 11.33x | 1.74% | 45.82B | |
| -40.88x | 13.55x | -36.8x | -.--% | 23.66B | |
| -17.88x | 3.19x | -5.8x | -.--% | 22.65B | |
| 22.1x | 4.38x | 11.36x | -.--% | 17.8B | |
| 22.89x | 4.47x | 14.73x | -.--% | 16.08B | |
| 749.62x | 17.63x | 96.27x | -.--% | 14.14B | |
| -14.77x | 3784.25x | -18.76x | -.--% | 13.09B | |
| -440.28x | 31.6x | -1979.01x | -.--% | 13B | |
| Average | 32.72x | 430.20x | -209.32x | 0.2% | 21.63B | |
| Weighted average by Cap. | 29.30x | 237.46x | -108.72x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- BOLT Stock
- Valuation Bolt Biotherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition